While antitumor effects of the CD40L-CD40 axis in dendritic cell activation by CD4+ T cells have been documented (4–7, 40, 41), its ability to remodel the tumor microenvironment has previously been studied (42, 43). The gene discussed is CD40; the disease is neoplasm.